Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model

mBio

Volumn 7, Issue 2, 2016, Pages

  Memoli, Matthew J ^a   Shaw, Pamela A ^b   Han, Alison ^a   Czajkowski, Lindsay ^a   Reed, Susan ^a   Athota, Rani ^a   Bristol, Tyler ^a   Fargis, Sarah ^a   Risos, Kyle ^a   Powers, John H ^a   Davey, Richard T ^a   Taubenberger, Jeffery K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS SIALIDASE; H1N1 VIRUS HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GOLD STANDARD; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNITY; IMMUNOLOGICAL PARAMETERS; INCIDENCE; INFLUENZA A VIRUS (H1N1); MALE; NONHUMAN; NORMAL HUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SYMPTOM; VIRUS SHEDDING; WILD TYPE; ADOLESCENT; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; PHYSIOLOGY; UNITED STATES; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84965180584     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00417-16     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. 2010. Estimates of deaths associated with seasonal influenza—United States, 1976–2007. MMWR Morb Mortal Wkly Rep 59:1057–1062.
2. Stohr K, Esveld M. 2004. Public health. Will vaccines be available for the next influenza pandemic? Science 306:2195–2196. http://dx.doi.org/10.1126/science.1108165.
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186. http://dx.doi.org/10.1001/jama.289.2.179.
4. Lambert LC, Fauci AS. 2010. Influenza vaccines for the future. N Engl J Med 363:2036–2044. http://dx.doi.org/10.1056/NEJMra1002842.
5. Nichol KL. 2003. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21:1769-1775. http://dx.doi.org/10.1016/S0264-410X(03)00070-7.
6. Nichol KL. 2008. Efficacy and effectiveness of influenza vaccination. Vaccine 26(Suppl 4):D17–D22. http://dx.doi.org/10.1016/j.vaccine.2008.07.048.
7. Cox RJ. 2013. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother 9:405-408. http://dx.doi.org/10.4161/hv.22908.
8. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767–777.
9. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in man. Br Med Bull 35:69–75.
10. Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG. 1977. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) 79: 321–332.
11. Salk JE, Pearson HE, Brown PN, Smyth CJ, Francis T, Jr. 1945. Immunization against influenza with observations during an epidemic of influenza A one year after vaccination. Am J Hyg 42:307–322.
12. Members of the Commission on Influenza, Board for the Investigation and Control of Influenza and Other Epidemic Diseases in the Army, Preventative Medicine Service, Office of the Surgeon General, United States Army. 1944. A clinical evaluation of vaccination against influenza. JAMA 124:982–985.
13. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. 2010. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 10:18. http://dx.doi.org/10.1186/1471-2288-10-18.
14. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. 2011. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30:1081–1085. http://dx.doi.org/10.1097/INF.0b013e3182367662.
15. Centers for Disease Control and Prevention. 24 June 2015. Seasonal influenza vaccine effectiveness, 2005-2015. Accessed 5 November 2015. http://www.cdc.gov/flu/professionals/vaccination/effectivenessstudies.htm.
16. Centers for Disease Control and Prevention. 2013. Interim adjusted estimates of seasonal influenza vaccine effectiveness -United States, February 2013. MMWR Morb Mortal Wkly Rep 62:119–123.
17. Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, Clark T, Katz JM, Zambon MC. 2012. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 30:210-217. http://dx.doi.org/10.1016/j.vaccine.2011.11.019.
18. Wagner R, Göpfert C, Hammann J, Neumann B, Wood J, Newman R, Wallis C, Alex N, Pfleiderer M. 2012. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine 30: 4113–4122. http://dx.doi.org/10.1016/j.vaccine.2012.02.077.
19. Memoli MJ, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K, Fargis S, Stein M, Dunfee RL, Shaw PA, Davey RT, Taubenberger JK. 2015. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 60:693–702. http://dx.doi.org/10.1093/cid/ciu924.
20. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24:157–160.
21. Monto A, Kendal A. 1973. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 301:623-625. http://dx.doi.org/10.1016/S0140 -6736(73)92196-X.
22. Murphy BR, Kasel JA, Chanock RM. 1972. Association of serum antineuraminidase antibody with resistance to influenza in man.NEngl J Med 286:1329–1332. http://dx.doi.org/10.1056/NEJM197206222862502.
23. Schild GC. 1969. Antibody against influenza A2 virus neuraminidase in human sera. J Hyg (Lond) 67:353–365.
24. Virelizier JL, Allison AC, Schild GC. 1979. Immune responses to influenza virus in the mouse, and their role in control of the infection. Br Med Bull 35:65–68.
25. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Niño D, Belmont JW. 2013. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207:974-981. http://dx.doi.org/10.1093/infdis/jis935.
26. Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. 2015. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis 212:1191–1199. http://dx.doi.org/10.1093/infdis/jiv195.
27. Powers JH, Guerrero ML, Leidy NK, Fairchok MP, Rosenberg A, Hernández A, Stringer S, Schofield C, Rodríguez-Zulueta P, Kim K, Danaher PJ, Ortega-Gallegos H, Bacci ED, Stepp N, Galindo-Fraga A, Clair KS, Rajnik M, McDonough EA, Ridoré M, Arnold JC, Millar EV, Ruiz-Palacios GM. 2016. Development of the Flu-PRO: a patientreported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis 16:1. http://dx.doi.org/10.1186/s12879-015-1330-0.
28. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC. 2013. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87:9290–9300. http://dx.doi.org/10.1128/JVI.01203-13.
29. Krafft AE, Russell KL, Hawksworth AW, McCall S, Irvine M, Daum LT, Connoly JL, Reid AH, Gaydos JC, Taubenberger JK. 2005. Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification. J Clin Microbiol 43:1768-1775. http://dx.doi.org/10.1128/JCM.43.4.1768-1775.2005.